Compared with placebo, treatment of
depressed systolic heart failure patients with escitalopram will result in a significant improvement in symptoms of depression at six months, when measured using the Cardiac Depression Scale.
Compared with placebo, treatment of
depressed systolic heart failure patients with escitalopram will result in a significant improvement in symptoms of depression at six months, when measured using the Hamilton Depression Rating Scale.